A. In general adult population having anti-SS-A antibodies, the profile of
1. Rodriguez-Perez N, Rodriguez-Navedo Y, Font YM, Vila LM.
Inflammatory myopathy as the initial presentation of cryoglobulinaemic vasculitis. BMJ Case Rep. 2013;2013:bcr2013010117.
2. Aoki A, Ono S, Ueda A, Hagiwara E, Tsuji T, Misumi M, et al.
Myositis in primary Sjogren's syndrome: clinical and pathological
report. Mod Rheumatol. 2003;13(1):57–61.
3. Robbins A, Hentzien M, Toquet S, Didier K, Servettaz A, Pham B-
N, et al. Diagnostic Utility of Separate Anti-Ro60 and Anti-Ro52/
TRIM21 Antibody Detection in Autoimmune Diseases. Front
Immunol. 2019;10:444.
4. Kubo M, Ihn H, Asano Y, Yamane K, Yazawa N, Tamaki K.
Prevalence of 52-kd and 60-kd Ro/SS-A autoantibodies in Japanese
patients with polymyositis/dermatomyositis. J Am Acad Dermatol.
2002;47(1):148–51.
5. Eloranta ML, Barbasso Helmers S, Ulfgren AK, Ronnblom L, Alm
GV, Lundberg IE. A possible mechanism for endogenous activation of the type I interferon system in myositis patients with anti-
Jo-1 or anti-Ro 52/anti-Ro 60 autoantibodies. Arthritis Rheum.
2007;56(9):3112–24.
6. Tatebe N, Sada K-E, Asano Y, Zeggar S, Hiramatsu S, Miyawaki Y,
et al. Anti-SS-A /Ro antibody positivity as a risk factor for relapse
in patients with polymyositis/dermatomyositis. Mod Rheumatol.
2018;28(1):141–6.
7. Temmoku J, Sato S, Fujita Y, Asano T, Suzuki E, Kanno T, et al.
Clinical significance of myositis-specific autoantibody profiles in
Japanese patients with polymyositis/dermatomyositis. Medicine.
2019;98(20):e15578.
8. Boccitto M, Wolin SL. Ro60 and Y RNAs: structure, functions, and roles in autoimmunity. Crit Rev Biochem Mol Biol.
2019;54(2):133–52.
Ro52-Ro60+ was found in 24%.3 However, the profile of Ro52-Ro60+
seems to be extremely rare in Japanese patients with polymyositis/dermatomyositis (PM/DM),4 and Sjögren's syndrome with myositis having
only anti-SS-A antibody is also rare.2 Anti-SS-A antibody could induce
PM/DM through activating interferon-α production.5 Recent studies
reported that anti-SS-A/Ro52 antibody was a risk factor for relapse in
PM/DM6 and associated with poor prognosis in anti-MDA5-antibody-
positive PM/DM.7 Anti-SS-A/Ro60 antibody can function as a Y RNA-
free protein,8 but the details are still unclear. These studies mentioned
not about anti-SS-A/Ro60, but only about anti-SS-A/Ro52. We suggest
a possibility that not only anti-SS-A/Ro52 but also anti-SS-A/Ro60 may
contribute to the resistance in the same way.
K E Y WO R D S
azathioprine, intravenous immunoglobulin, methotrexate, myositis,
Sjögren's syndrome, tacrolimus
AC K N OW L E D G M E N T
None.
C O N FL I C T O F I N T E R E S T
The authors declare no conflict of interest.
D EC L A R AT I O N S EC T I O N
Approval of the research protocol: N/A.
Informed consent: Informed consent was obtained.
How to cite this article: Kokubu H, Hamaguchi Y, Kato T,
Registry and the Registration No. of the study/trial: N/A.
Tanaka T, Fujimoto N. Refractory myositis in a patient of
Animal Studies: N/A.
Sjögren’s syndrome having only anti-SS-A (60 kDa) antibody.
Hiraku Kokubu MD1
Yasuhito Hamaguchi MD, PhD2
Takeshi Kato MD, PhD1
Toshihiro Tanaka MD, PhD1
Noriki Fujimoto MD, PhD1
J Cutan Immunol Allergy. 2021;00:1–2. https://doi.
org/10.1002/cia2.12218
...
論文の公開元へ
